These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19595208)

  • 1. [Study on predictors of long term results for neo-adjuvant chemotherapy in locally advanced breast cancer].
    Huang O; Chen CM; Wu JY; Hu Z; Hou YF; Zhang JX; Liu GY; Di GH; Lu JS; Wu J; Shao ZM; Shen ZZ; Shen KW
    Zhonghua Wai Ke Za Zhi; 2009 Apr; 47(7):511-5. PubMed ID: 19595208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months.
    Huang O; Chen C; Wu J; Chen S; Chen X; Liu G; Hu Z; Lu J; Wu J; Shao Z; Shen Z; Shen K
    BMC Cancer; 2009 Oct; 9():375. PubMed ID: 19845944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors of survival in pathologic incomplete response patients with locally advanced breast cancer after neoadjuvant chemotherapy.
    Huang O; Jiang M; Chen XS; Wu JY; Chen WG; Li YF; Shen KW
    Cell Biochem Biophys; 2015 Mar; 71(2):1181-90. PubMed ID: 25427887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).
    Deo SV; Bhutani M; Shukla NK; Raina V; Rath GK; Purkayasth J
    J Surg Oncol; 2003 Dec; 84(4):192-7. PubMed ID: 14756429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: phase II study.
    Braud AC; Levy E; Feuilhade F; Otmezguine Y; Calitchi E; Kirova Y; Le Bourgeois JP
    Am J Clin Oncol; 2002 Jun; 25(3):303-7. PubMed ID: 12040294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
    Kountourakis P; Missitzis I; Doufexis D; Zobolas V; Pissakas G; Arnogiannaki N; Maliou S; Sotiropoulou A; Ardavanis A
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):221-8. PubMed ID: 20387073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A study of the combination of vinorelbine and epirubicin as neoadjuvant chemotherapy regimen in the treatment of locally advanced breast cancer].
    Chen CM; Shen KW; Liu GY; Wu J; Lu JS; Zhuang CJ; Han QX; Liu BL; Shao ZM; Shen ZZ
    Zhonghua Wai Ke Za Zhi; 2006 Jun; 44(11):745-7. PubMed ID: 16836921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
    Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
    Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
    Ardavanis A; Scorilas A; Tryfonopoulos D; Orphanos G; Missitzis I; Karamouzis M; Chrysochoou M; Sotiropoulou A; Arnogiannaki N; Ioannidis G; Pissakas G; Rigatos G
    Oncologist; 2006 Jun; 11(6):563-73. PubMed ID: 16794236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
    Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
    J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer.
    Ma CD; Chen CM; Chen XS; Liu GY; Di GH; Wu J; Lu JS; Yang WT; Chen JY; Shao ZM; Shen ZZ; Shen KW
    Anticancer Res; 2008; 28(5B):3093-7. PubMed ID: 19031963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
    French Adjuvant Study Group
    J Clin Oncol; 2001 Feb; 19(3):602-11. PubMed ID: 11157009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.
    Boccardo F; Amadori D; Guglielmini P; Sismondi P; Farris A; Agostara B; Gambi A; Catalano G; Faedi M; Rubagotti A
    Oncology; 2010; 78(3-4):274-81. PubMed ID: 20530973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options for locally advanced breast cancer--experience in an Asian tertiary hospital.
    Chong HY; Taib NA; Rampal S; Saad M; Bustam AZ; Yip CH
    Asian Pac J Cancer Prev; 2010; 11(4):913-7. PubMed ID: 21133600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
    Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
    J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
    Sarid D; Ron IG; Sperber F; Stadler Y; Kahan P; Kovner F; Ben-Yosef R; Marmor S; Grinberg Y; Maimon N; Weinstein J; Yaal-Hahoshen N
    Clin Drug Investig; 2006; 26(12):691-701. PubMed ID: 17274676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.